Literature DB >> 11590286

Severe acute renal failure in malaria.

K S Mehta1, A R Halankar, P D Makwana, P P Torane, P S Satija, V B Shah.   

Abstract

BACKGROUND: We have noticed a recent rise in the incidence and severity of acute renal failure (ARF) in malaria. AIM: To study the incidence, severity and outcome of ARF in malaria. SETTING AND
DESIGN: It is a retrospective analysis of data of one year from a tertiary medical centre in a metropolitan city.
MATERIALS AND METHODS: Patients with ARF and smear positive malaria were evaluated. STATISTICAL ANALYSIS: Results were expressed as mean, range and standard deviation.
RESULTS: Out of 402 detected smear positive malaria, 24 had ARF. Eighteen were of the age group 21-40 years. Plasmodium falciparum (PF) was detected in 16, Plasmodium vivax in three, and mixed infection in five. Non-oliguric ARF was seen in 14. Eighteen showed severe ARF (Serum creatinine >5 mg%). Twenty-two patients needed dialysis. Prolonged ARF lasting for 2-6 weeks was seen in eight. Seventeen patients recovered completely, while seven showed fatal combination of disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), severe ARF and PF malaria. No response was seen to chloroquine and artesunate given alone and twenty patients required quinine.
CONCLUSION: ARF necessitating dialysis was seen in 92% of patients with ARF in malaria. PF infection, severe ARF, DIC and ARDS were poor prognostic factors. Resistance was noted to both chloroquine and artesunate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590286

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  21 in total

1.  Prevention and treatment of vivax malaria.

Authors:  J Kevin Baird; Eli Schwartz; Stephen L Hoffman
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

Review 2.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

3.  Clinical profile of severe malaria: study from a tertiary care center in north India.

Authors:  Shafali Nandwani; Apurva Pande; Mahip Saluja
Journal:  J Parasit Dis       Date:  2012-11-21

4.  Acute Kidney Injury in Children with Plasmodium falciparum Malaria: Determinants for Mortality.

Authors:  Rajniti Prasad; Om P Mishra
Journal:  Perit Dial Int       Date:  2015-10-01       Impact factor: 1.756

5.  Protein kinase C (PKC) dependent induction of tissue factor (TF) by mesangial cells in response to inflammatory mediators and release during apoptosis.

Authors:  Detlef Lang; Martin Terstesse; Frank Dohle; Philip Bangen; Bernhard Banas; Hans-Gerd Pauels; Stefan Heidenreich
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

6.  Induction of proinflammatory cytokines and nitric oxide by Trypanosoma cruzi in renal cells.

Authors:  Gabriel M de Oliveira; Nobuko Yoshida; Elisa M S Higa; Sérgio Shenkman; Monique Alves; Daniela Staquicini; Cynthia Cascabulho; Nestor Schor
Journal:  Parasitol Res       Date:  2011-02-17       Impact factor: 2.289

Review 7.  Community-acquired acute kidney injury in tropical countries.

Authors:  Vivekanand Jha; Sreejith Parameswaran
Journal:  Nat Rev Nephrol       Date:  2013-03-05       Impact factor: 28.314

8.  Acute Renal Failure in Patients with Severe Falciparum Malaria: Using the WHO 2006 and RIFLE Criteria.

Authors:  Vipa Thanachartwet; Varunee Desakorn; Duangjai Sahassananda; Ko Ko Yazar Kyaw Win; Thanom Supaporn
Journal:  Int J Nephrol       Date:  2013-01-29

9.  A Retrospective Analysis of Outcome in Malaria Patients Admitted into a Multidisciplinary Intensive Care Unit of a Tertiary Care Teaching Hospital.

Authors:  Bharath Cherukuri
Journal:  Anesth Essays Res       Date:  2021-03-22

10.  Clinical profile of malaria at a tertiary care teaching hospital in North India.

Authors:  Ritu Karoli; Shobhit Shakya; Nikhil Gupta; Vineeta Mittal; Anil Kumar Upadhyay
Journal:  Trop Parasitol       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.